Advertisement

Experimental Evidence for Enhancement of Thrombolysis by Conventional Thrombolytic Drugs

  • Paolo Golino
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)

Abstract

Braunwald et al.’s hypothesis that the extent of myocardial injury reflects the degree of imbalance between myocardial oxygen supply and oxygen requirements gained wide acceptance in the 1970s as a result of observations in both experimental animals and patients [1]. It soon became clear that reduction of myocardial oxygen requirements by itself only modestly attenuated the extent of ischemic injury [2]. Subsequently, major efforts have been made to develop techniques that directly restore nutritive myocardial perfusion. In particular, with the knowledge that thrombotic coronary occlusion occurs in the vast majority of patients in the early phase of acute myocardial infarction [3], a rationale for thrombolytic therapy existed. Administration of drugs capable of lysing the intracoronary thrombus seems particularly attractive because its simplicity makes it applicable to most of the patients with acute myocardial infarction. This review summarizes advances related to thrombolytis and suggests additions to or alterations in thrombolytic therapy that could make it even more effective as a therapeutic intervention in the future.

Keywords

Acute Myocardial Infarction Plasminogen Activator Thrombolytic Therapy Thrombolytic Agent Intravenous Streptokinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67, 1971.PubMedGoogle Scholar
  2. 2.
    Sobel BE, Braunwald E. The management of acute myocardial infarction. In Braunwald E (ed). Heart Disease: A Textbook of Cardiovascular Medicine, 2nd ed. Philadelphia: WB Saunders, 1984:1301.Google Scholar
  3. 3.
    De Wood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897, 1980.CrossRefGoogle Scholar
  4. 4.
    Chamberlain DA. Unanswered questions in thrombolysis. Am J Cardiol 63:34A, 1989.CrossRefGoogle Scholar
  5. 5.
    Califf RM, Topol EJ, George BS, Boswick JM, Lee KL, Stump D, Dillon J, Abbottsmith C, Candela RJ, Kereiakes DJ, ONeill WW, Stack RS. Characteristics and outcome of patiencs in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. Circulation 77:1090, 1988.PubMedGoogle Scholar
  6. 6.
    Morgan CD, Roberts RS, Haq A, Baigrie RS, Daly PA, Gent M, Armstrong PW, for the TPAT Study Group. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: Results from the Tissue Plasminogen Activator Toronto (TPAT) placebo-controlled trial. J Am Coll Cardiol 17:1451, 1991.PubMedGoogle Scholar
  7. 7.
    Topol EJ, Morris DC, Smalling RW, Schumacher RR, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossbard EB, O’Neill WW. A multicenter. randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 9:1205, 1987.PubMedGoogle Scholar
  8. 8.
    Anderson JL, Marshall HW, Askins JC, Lutz R, Sorensen SG, Menlove RL, Yanowitz FG, Hagan AD. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. Circulation 70:606, 1984.PubMedGoogle Scholar
  9. 9.
    Chesebro JH, Knatterud G, Roberts R, Borer S, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142, 1987.PubMedGoogle Scholar
  10. 10.
    Armstrong PW, Baigrie RS, Daly PA, Haq A, Gent M, Roberts RS, Freeman MR, Burns R, Liu P, Morgan CD. Tissue plasminogen activator: Toronto (TPAT) Placebo-Controlled Randomized Trial in Acute Myocardial Infarction. J Am Coll Cardiol 13:1469, 1989.PubMedGoogle Scholar
  11. 11.
    Verstraete M, Brower RW, Collen D, Dunning AJ, Lubsen J, Michel PL, Schofer J, Vanhaecke J, Van de Werf F, Bleifeld W, Charbonnier B, de Bono DP, Lennane RJ, Mathey DG, Raynaud P, Vahanian A, van de Kley GA, Von Essen R. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction (ECSG-I). Lancet 1:965, 1985.CrossRefGoogle Scholar
  12. 12.
    Stack RS, O’Connor CM, Mark DB, Hinohara T, Phillips HR, Lee MM, Ramirez NM, O’Callaghan WG, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Califf RM. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intra venous streptokinase. Circulation 77:151, 1988.PubMedGoogle Scholar
  13. 13.
    PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1:863, 1989.Google Scholar
  14. 14.
    Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, Brower RW, DeBono DP, Huhmann W, Lubsen J, Meyer J, Rutsch W, Schmidt W, VonEssen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1:842, 1985.PubMedCrossRefGoogle Scholar
  15. 15.
    Whitlow PL, Bashore TM. Catheterization/Rescue Angioplasty Following Thrombolysis (CRAFT) study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase. J Am Coll Cardiol 17:276A, 1991.Google Scholar
  16. 16.
    Neuhaus K, Tebbe U, Gottwik M, Weber M, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser K, Huhmann W, Howpp H, Alber G, Sheikhzadeh A, Schneider B. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 12:581, 1988.PubMedGoogle Scholar
  17. 17.
    Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson IL, Harrelson-Woodlief L, Wall TC, Phillips HR, Abbottsmith CW, Candela RJ, Flanagan WH, Sasahara AA, Mantell SJ, Lee KL. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: Results of Thrombolysis and Angioplasty in Myocardial Infarction — phase 5 randomized trial. Circulation 83:1543, 1991.PubMedGoogle Scholar
  18. 18.
    TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI IIA results. JAMA 260:2849, 1988.CrossRefGoogle Scholar
  19. 19.
    Neuhaus K-L, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 19:885, 1992.PubMedGoogle Scholar
  20. 20.
    Hogg KJ, Gemmill JD, Burns JMA, Lifson WK, Rae AP, Dunn FG, Hillis WS. Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction. Lancet 335:254, 1990.PubMedCrossRefGoogle Scholar
  21. 21.
    Relik-van Wely L, Visser RF, van der Pol J, Bartholomeus I, Couvee JE, Drost H, Vet A, Klomps HC, van Ekelen W, Van der Berg F, Krauss X. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: Results of the Anistreplase Reocclusion Multicenter Study (ARMS). Am J Cardiol 68:296, 1991.PubMedCrossRefGoogle Scholar
  22. 22.
    Carney RJ, Murphy GA, Brandt TR, Daley PJ, Pickering E, White HJ, McDonough TJ, Vermilya SK, Teichman SL, for the RAAMI Study Investigators. Randomized angiographic trial of recombinant tissue-type plasminogen activator (Alteplase) in myocardial infarction. J Am Coll Cardiol 20:17, 1992.PubMedGoogle Scholar
  23. 23.
    Smalling RW, Schumacher R, Morris D, Harder K, Fuentes F, Valentine RP, Battey LL, Merhige M, Pitts DE, Lieberman HA, Nishikawa A, Adyanthaya A, Hopkins A, Grossbard E. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 15:915, 1990.PubMedGoogle Scholar
  24. 24.
    Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ, for the TAMI-7 Study Group. Accelerated plasminogen activator dose regimens for coronary thrombolysis. J Am Coll Cardiol 19:482, 1992.PubMedGoogle Scholar
  25. 25.
    Forrester JS. New standard for success of thrombolytic therapy. Circulation 92:2026, 1996.Google Scholar
  26. 26.
    Collen D. Molecular mechanism of action of newer thrombolytic agents. J Am Coll Cardiol 10:11B, 1987.PubMedGoogle Scholar
  27. 27.
    Eidt JF, McNatt J, Wydro RM, Yao SK, Allison P, Garramone S, Peters L, Livingston DJ, Buja LM, Willerson JT. Coronary thrombolysis with a variant of human tissue-type plasminogen activator in a canine preparation: Slightly enhanced thrombolysis and prolonged time to reocclusion. Cor Art Dis 2:931, 1991.Google Scholar
  28. 28.
    Gardell SJ, Ramjit DR, Stabilito H, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung JS, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 84:244, 1991.PubMedGoogle Scholar
  29. 29.
    Markland FS, Friedrichs GS, Pewitt SR, Lucchesi BR. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 90:2448, 1994.PubMedGoogle Scholar
  30. 30.
    Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 74:838, 1986.PubMedGoogle Scholar
  31. 31.
    Collen D, Stump DC, Van de Werf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J 112:1083, 1986.PubMedCrossRefGoogle Scholar
  32. 32.
    Collen D, Van de Werf F. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue type plasminogen activator (rt-PA) and recombinant single chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. Am J Cardiol 60:431, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Bode C, Schuler G, Nordt T, et al. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and re-combinant tissue-type plasminogen activator in acute myocardial infarction. Circulation 81:907, 1990.PubMedGoogle Scholar
  34. 34.
    Bode C, Runge MS, Schonermark S, et al. Conjugation to an antifibrin antibody enhances the fibrinolytic potency of single-chain urokinase (scuPA). Clin Res 36:265A, 1988.Google Scholar
  35. 35.
    Hanson SR, Paxton LD, Harker LA. Iliac artery mural thrombus formation: Effect of antiplatelet therapy on 111In-platelet deposition in baboons. Arteriosclerosis 6:511, 1986.PubMedGoogle Scholar
  36. 36.
    Salimi A, Oliver GC Jr, Lee J, Sherman LA. Continued incorporation of circulating radiolabeled fibrinogen intopreformed coronary artery thrombi. Circulation 56:213, 1977.PubMedGoogle Scholar
  37. 37.
    Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 74:583, 1986.PubMedGoogle Scholar
  38. 38.
    Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation ot plasminogen. Biochemistry 25:4033, 1986.PubMedCrossRefGoogle Scholar
  39. 39.
    Mickelson JK, Simpson PJ, Lucchesi BR. Effects of heparin and intravenous tissue plasminogen activator or streptokinase in a canine model of coronary artery thrombosis. Clin Res 35:305A, 1987.Google Scholar
  40. 40.
    Hsia J, Hamilton WP, Kleiman N, Roberts R, Chairman BR, Ross AM for the HART Investigators. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433, 1990.PubMedCrossRefGoogle Scholar
  41. 41.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673, 1993.CrossRefGoogle Scholar
  42. 42.
    Chapman I. Morphogenesis ot occluding coronary artery thrombosis. Arch Pathol 80:256, 1965.PubMedGoogle Scholar
  43. 43.
    Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood 65:1299, 1985.PubMedGoogle Scholar
  44. 44.
    Harfenist EJ, Packham MA, Mustard JF. Comparison of the interactions of fibrinogen and soluble fibrin with washed rabbit platelets stimulated with ADP. Thromb Haemost 53:183, 1985.PubMedGoogle Scholar
  45. 45.
    Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77:670, 1988.PubMedGoogle Scholar
  46. 46.
    Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circularion 69:1161, 1984.Google Scholar
  47. 47.
    Ashton JH, Schmitz JM, Campbell WB, et al. Inhibibon of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res 59:568, 1986.PubMedGoogle Scholar
  48. 48.
    Ashton JH, Benedict CR, Fitzgerald C, et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 73:572, 1986.PubMedGoogle Scholar
  49. 49.
    Golino P, Ashton JH, McNatt J, et al. Simultaneous administration of thromboxane A2 and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model ot coronary thrombosis. Circulation 79:911, 1989.PubMedGoogle Scholar
  50. 50.
    Golino P, Yao SK, Rosolowsky M, De Clerck F, Buja LM, Willerson JT. Simultaneous blockade of thromboxane A2 receptors and inhibition of thromboxane A2 synthase is more effective in enhancing thrombolysis and preventing reocclusion after tissue plasminogen activator than blockade of thromboxane A2 receptors alone. Clin Res 37:S18A, 1989.Google Scholar
  51. 51.
    Golino P, Rosolowsky M, Sheng-Kun Y, McNatt J, De Clerck F, Buja I M, Willerson JT. Endogenous prostaglandin endoperoxides and prosracyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest 86:1095, 1990.PubMedCrossRefGoogle Scholar
  52. 52.
    Yao SK, Ober JC, Ferguson JJ, Maffrand J-P, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 267:H488, 1994.PubMedGoogle Scholar
  53. 53.
    Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM, Willerson JT. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation 89:2822, 1994.PubMedGoogle Scholar
  54. 54.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17. 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349, 1988.Google Scholar
  55. 55.
    Marguerie GA, Plow EF. The fibrinogen-dependent pathway ot platelet aggregation. Ann N Y Acad Sci 408:556, 1983.PubMedCrossRefGoogle Scholar
  56. 56.
    Thorsen LI, Brosstad F, Gogstad G, Sletten K, Solum NO. Competitions between fibrinogen with its degradation produces for interactions with the platelet-fibrinogen receptor. Thromb Res 44:611, 1986.PubMedCrossRefGoogle Scholar
  57. 57.
    Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310:1137, 1984.PubMedCrossRefGoogle Scholar
  58. 58.
    Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913, 1982.CrossRefGoogle Scholar
  59. 59.
    Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of artetial damage and wall shear rate on platelet deposition: Ex vivo study in a swine model. Arteriosclerosis 6:312, 1986.PubMedGoogle Scholar
  60. 60.
    Davies MJ, Thomas T. The pathological basis and microanatomy of occlusive thrombus formation in human coronary arteries. Phil Trans R Soc Lond (Series B) 294:225, 1981.CrossRefGoogle Scholar
  61. 61.
    Willerson JT, Golino P, Eidt JF, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications. Circulation 80:198, 1989-62.PubMedGoogle Scholar
  62. 62.
    Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 77:1213, 1988.PubMedGoogle Scholar
  63. 63.
    Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 8(Suppl. B): 2B, 1986.PubMedGoogle Scholar
  64. 64.
    Walsh PN. The role of platelets in the contact phase of blood coagulation. Br J Haematol 22:237, 1972.PubMedGoogle Scholar
  65. 65.
    Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77:142, 1988.PubMedGoogle Scholar
  66. 66.
    Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue type plasminogen activator. Circulation 88:1718, 1989.Google Scholar
  67. 67.
    Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after Streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 10:527, 1987.PubMedGoogle Scholar
  68. 68.
    Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 81:1284, 1988.PubMedGoogle Scholar
  69. 69.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77:678, 1988.PubMedGoogle Scholar
  70. 70.
    Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest 88:1568, 1991.PubMedGoogle Scholar
  71. 71.
    Ware JA, Smith M, Salzman EW. Synergism of platelet aggregating agents: Role of elevation of cytoplasmic calcium. J Clin Invest 80:267, 1987.PubMedGoogle Scholar
  72. 72.
    Fitzgerald DJ. Platelet inhibition with an antibody to glycoprotein IIb/IIIa. Circulation 80:1918, 1989.PubMedGoogle Scholar
  73. 73.
    Ashton JH, Ogletree ML, Michel IM, Golino P, et al. Cooperative mediation by serotonin S2. and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 76:952, 1987.PubMedGoogle Scholar
  74. 74.
    De Clerck F, Xhonneux L, Van Gorp, et al. S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM13.177): Enhanced anti-platelet effect. Thromb Haemost 56:236, 1986.PubMedGoogle Scholar
  75. 75.
    Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 55:69, 1986.PubMedCrossRefGoogle Scholar
  76. 76.
    Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522, 1994.PubMedGoogle Scholar
  77. 77.
    Klement P, Hirsh J, Maraganore J, Fenton J, Weitz J. Effects of heparin and hirulog on t-PA induced thrombolysis in a rat model. Thromb Haemost 68:64, 1992.PubMedGoogle Scholar
  78. 78.
    Haskel EJ, Prager NA, Sobel BE, Abenschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83:1048, 1991.PubMedGoogle Scholar
  79. 79.
    Cannon CP, Mc Cabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desolphatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993, 1994.PubMedCrossRefGoogle Scholar
  80. 80.
    Lee LV, McCabe CH, Antman EM, Koch M, Wilensky R, Stringer K, Hochman J, Mueller HS, Henry TD, Kleiman N, Steingart RM, Wasserman H, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the TIMI 6 trial. J Am Coll Cardiol (Special issue): 344A, 1994.Google Scholar
  81. 81.
    Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622, 1993.PubMedGoogle Scholar
  82. 82.
    Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 19:1065, 1992.PubMedGoogle Scholar
  83. 83.
    Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12:1111, 1992.PubMedGoogle Scholar
  84. 84.
    Ragni M, Cirillo P, Pascucci I, Scognamiglio A, D’Andrea D, Eramo N, Ezekowitz MD, Pawashe A, Chiariello M, Golino P. A monoclonal antibody against tissue factor shortens tissue-plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation, in press.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Paolo Golino

There are no affiliations available

Personalised recommendations